MedTrace Logo

Comparing the Extent to Which AQ280 is Made Available in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

NCT07093008 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-08-05

No results posted yet for this study

Summary

This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral suspension formulation in healthy participants.

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

AQ280 Capsule

AQ280 administered orally in capsule formulation.

DRUG

AQ280 Tablet for Oral Suspension

AQ280 administered orally in tablet for oral suspension formulation.

DRUG

Placebo Capsule

Placebo administered orally in capsule formulation.

DRUG

Placebo Tablet for Oral Suspension

Placebo administered orally in tablet for oral suspension formulation.

Sponsors & Collaborators

  • AQILION AB

    lead INDUSTRY

Principal Investigators

  • Jan Törnell · AQILION AB

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-13
Primary Completion
2025-07-16
Completion
2025-07-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07093008 on ClinicalTrials.gov